title: Renal cortical remodelling by NO-synthesis blockers in rats is prevented by angiotensin-converting enzyme inhibitor and calcium channel blocker.
abstract: The cortical remodelling was studied when chronically nitric oxide synthesis (NOs) blockade (L-NAME-induced) hypertensive rats are simultaneously treated, or not, with angiotensin-converting enzyme inhibitor or calcium channel blocker. Four groups of eight rats each were studied as follows: Control (C), L-NAME (L), L-NAME+Enalapril (L+E) and L-NAME+Verapamil (L+V). The systolic blood pressure (SBP) was weekly recorded. The cortex of the left kidneys was analysed according to the vertical section design. The volume-weighted mean glomerular volume (VWGV) was made through the "point-sampled intercepts" method. Enalapril and verapamil were efficient in reducing the SBP in rats submitted to NOs blockade. Glomeruli had considerable alterations in L group rats (glomerular hypertrophy or sclerosis) and tubular atrophy. The VWGV was 100% greater in L group rats than in the C group rats, while it was 30% smaller in L+E and L+V groups than in L group. The tubular volume was 30-50% greater, while the tubular length was 20-30% smaller in the L group than in the other groups. The renal cortical region showed glomerular sclerosis/hypertrophy and tubular remodelling in rats with NOs blockade that was efficiently prevented with the simultaneous treatment with enalapril or verapamil.
authors.affiliation: Laboratory of Morphometry & Cardiovascular Morphology, Biomedical Centre, Institute of Biology, State University of Rio de Janeiro (UERJ), Brazil. mandarim@uerj.br
authors.forename: C A
authors.initials: CA
authors.lastname: Mandarim-de-Lacerda
authors.forename: L M
authors.initials: LM
authors.lastname: Pereira
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D004656:Enalapril / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006978:Hypertension, Renovascular / Q000201:enzymology / Q000503:physiopathology / Q000517:prevention & control*; D007672:Kidney Cortex / Q000187:drug effects* / Q000201:enzymology / Q000503:physiopathology; D008297:Male; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D014700:Verapamil / Q000627:therapeutic use
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D004791:Enzyme Inhibitors; D004656:Enalapril; D014700:Verapamil; D019001:Nitric Oxide Synthase; D019331:NG-Nitroarginine Methyl Ester